Advertisement

Buy track record

How this insider's open-market purchases have performed
100%
of buys now in profit
1 up · 0 down
Avg return since buy+605.9%
Median return+605.9%
Best trade+605.9%
Worst trade+605.9%
Buys scored1 (+1 n/a)
Average return by holding period — separates good entry timing from riding one long winner
After 1 month +0.1% 100% won · 1 trade
After 3 months −17.0% 0% won · 1 trade
After 6 months +23.0% 100% won · 1 trade
After 12 months +16.1% 100% won · 1 trade
DateCompany90d trendBuy priceValueΔOwn1M3M6M12MTo date
Jul 22, 2022 RVMD $20 $1M +476% +0.1% −17.0% +23.0% +16.1% +605.9%
How this is calculated. We score only open-market purchases (SEC code P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 1 scored trade, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$1.9M
2 trades
Open-market sells
$71.54M
45 trades
Net flow
−$69.64M
Net selling
Total filings
72
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
MRNA
Sell Kim Lorence H. · Chief Financial Officer · Open-market sale · filed Feb 27, 2020

Kim Lorence H. sold $2.6K of MRNA.

−$2.6K
100 sh @ $26
MRNA
Sell Kim Lorence H. · Chief Financial Officer · Open-market sale · filed Feb 11, 2020 ΔOwn −2.5%

Kim Lorence H. sold $767.8K of MRNA, trimming their stake 2%.

−$767.8K
33,295 sh @ $23
MRNA
Sell Kim Lorence H. · Chief Financial Officer · Open-market sale · filed Jan 29, 2020 ΔOwn −0.1%

Kim Lorence H. sold $21K of MRNA.

−$21K
900 sh @ $23
MRNA
Sell Kim Lorence H. · Chief Financial Officer · Open-market sale · filed Jan 29, 2020 ΔOwn −1.7%

Kim Lorence H. sold $547.8K of MRNA, trimming their stake 2%.

−$547.8K
23,805 sh @ $23
MRNA
Sell Kim Lorence H. · Chief Financial Officer · Open-market sale · filed Jan 23, 2020 ΔOwn −0.1%

Kim Lorence H. sold $46.1K of MRNA.

−$46.1K
2,000 sh @ $23
Advertisement
MRNA
Option exercise Kim Lorence H. · Chief Financial Officer · Option exercise · filed Dec 9, 2019 ΔOwn +20%
+$4.73M
229,357 sh @ $21
MRNA
Option exercise Kim Lorence H. · Chief Financial Officer · Option exercise · filed Dec 9, 2019 ΔOwn +17%
+$4.73M
229,358 sh @ $21
MRNA
Sell Kim Lorence H. · Chief Financial Officer · Open-market sale · filed Dec 9, 2019 ΔOwn −5.6%

Kim Lorence H. sold $1.73M of MRNA, trimming their stake 6%.

−$1.73M
89,698 sh @ $19
MRNA
Sell Kim Lorence H. · Chief Financial Officer · Open-market sale · filed Dec 9, 2019 ΔOwn −9.8%

Kim Lorence H. sold $3.01M of MRNA, trimming their stake 10%.

−$3.01M
147,528 sh @ $20
MRNA
Sell Kim Lorence H. · Chief Financial Officer · Open-market sale · filed Dec 9, 2019 ΔOwn −0.1%

Kim Lorence H. sold $27.3K of MRNA.

−$27.3K
1,306 sh @ $21

Frequently asked questions

How is Kim Lorence H.'s win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from Kim Lorence H.'s SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.